233 related articles for article (PubMed ID: 32125151)
21. Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Park S; Song CS; Lin CL; Jiang S; Osmulski PA; Wang CM; Marck BT; Matsumoto AM; Morrissey C; Gaczynska ME; Chen Y; Mostaghel EA; Chatterjee B
Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31894239
[TBL] [Abstract][Full Text] [Related]
22. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
[TBL] [Abstract][Full Text] [Related]
23. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
[TBL] [Abstract][Full Text] [Related]
24. Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.
Adeniji A; Uddin MJ; Zang T; Tamae D; Wangtrakuldee P; Marnett LJ; Penning TM
J Med Chem; 2016 Aug; 59(16):7431-44. PubMed ID: 27486833
[TBL] [Abstract][Full Text] [Related]
25. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.
Penning TM
Expert Opin Ther Pat; 2017 Dec; 27(12):1329-1340. PubMed ID: 28895472
[TBL] [Abstract][Full Text] [Related]
26. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
[TBL] [Abstract][Full Text] [Related]
27. Design, Synthesis and Cytotoxicity Evaluation of Novel Indole Derivatives Containing Benzoic Acid Group as Potential AKR1C3 Inhibitors.
Sun M; Zhou Y; Zhuo X; Wang S; Jiang S; Peng Z; Kang K; Zheng X; Sun M
Chem Biodivers; 2020 Dec; 17(12):e2000519. PubMed ID: 33111427
[TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
[TBL] [Abstract][Full Text] [Related]
29. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Tilki D; Graefen M; Kluth LA; Briganti A; Mandel P; Montorsi F; Chun FKH; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):139-148. PubMed ID: 34054128
[TBL] [Abstract][Full Text] [Related]
30. Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
Yang JC; Xu P; Ning S; Wasielewski LJ; Adomat H; Hwang SH; Morisseau C; Gleave M; Corey E; Gao AC; Lara PN; Evans CP; Hammock BD; Liu C
Oncogene; 2023 Feb; 42(9):693-707. PubMed ID: 36596844
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Sun SQ; Gu X; Gao XS; Li Y; Yu H; Xiong W; Yu H; Wang W; Li Y; Teng Y; Zhou D
Oncotarget; 2016 Jul; 7(30):48050-48058. PubMed ID: 27385003
[TBL] [Abstract][Full Text] [Related]
32. Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.
Matsunaga T; Okumura N; Saito H; Morikawa Y; Suenami K; Hisamatsu A; Endo S; Ikari A
Chem Biol Interact; 2020 Dec; 332():109295. PubMed ID: 33096057
[TBL] [Abstract][Full Text] [Related]
33. AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Penning TM
Mol Cell Endocrinol; 2019 Jun; 489():82-91. PubMed ID: 30012349
[TBL] [Abstract][Full Text] [Related]
34. Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment.
He S; Chu X; Wu Y; Jiang J; Fang P; Chen Y; Liu Y; Qiu Z; Xiao Y; Li Z; Pan D; Zhang Q; Xie H; Xing S; Feng F; Liu W; Guo Q; Zhao L; Yang P; Sun H
J Med Chem; 2023 Jul; 66(14):9537-9560. PubMed ID: 37409679
[TBL] [Abstract][Full Text] [Related]
35. Transition from androgenic to neurosteroidal action of 5α-androstane-3α, 17β-diol through the type A γ-aminobutyric acid receptor in prostate cancer progression.
Xia D; Lai DV; Wu W; Webb ZD; Yang Q; Zhao L; Yu Z; Thorpe JE; Disch BC; Ihnat MA; Jayaraman M; Dhanasekaran DN; Stratton KL; Cookson MS; Fung KM; Lin HK
J Steroid Biochem Mol Biol; 2018 Apr; 178():89-98. PubMed ID: 29155210
[TBL] [Abstract][Full Text] [Related]
36. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
Swami U; Agarwal N
Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
[TBL] [Abstract][Full Text] [Related]
37. AKR1C3 as a target in castrate resistant prostate cancer.
Adeniji AO; Chen M; Penning TM
J Steroid Biochem Mol Biol; 2013 Sep; 137():136-49. PubMed ID: 23748150
[TBL] [Abstract][Full Text] [Related]
38. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.
Roumiguié M; Paoletti X; Neuzillet Y; Mathieu R; Vincendeau S; Kleinclauss F; Mejean A; Guy L; Timsit MO; Lebret T
Future Oncol; 2021 May; 17(14):1811-1823. PubMed ID: 33543650
[No Abstract] [Full Text] [Related]
39. Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model.
Maddeboina K; Jonnalagadda SK; Morsy A; Duan L; Chhonker YS; Murry DJ; Penning TM; Trippier PC
J Med Chem; 2023 Jul; 66(14):9894-9915. PubMed ID: 37428858
[TBL] [Abstract][Full Text] [Related]
40. The AKR1C3/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression.
Wang B; Wu S; Fang Y; Sun G; He D; Hsieh JT; Wang X; Zeng H; Wu K
J Cell Mol Med; 2020 Oct; 24(20):12032-12043. PubMed ID: 32902124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
